Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25 mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials.